Company Profile
Shanghai Bio-heart Biological Technology provides the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease.
Its portfolio also includes Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension, and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis. It is also involved in local administration and manufacturing services. Founded in 2014, the company is headquartered in Shanghai, China.